May 9, 2012
The National Institutes of Health (NIH) announced Thursday it is partnering with Pfizer Inc., AstraZeneca Plc., and Eli Lilly and Co. to find new uses for 24 existing drug compounds.
All the compounds have been shown to be safe, but they were shelved for being ineffective against the diseases they were developed to treat. Drugmakers typically spend $2 billion and 14 years bringing medicines to market. In the past, dozens of drugs that were originally developed for one disease have been repurposed for another -- usually by chance. For example, AZT (azidothymidine) was approved in the 1960s to treat cancer but abandoned for lack of efficacy. It later became the first effective treatment for HIV.
NIH will spend $20 million annually for researchers to find new uses for the 24 compounds. "We need to speed the pace at which we are turning discoveries into better health outcomes," said Dr. Francis Collins, the agency's director. "The idea here is not to depend on serendipity."
Scientists who discover a new use for a compound will be eligible for royalty payments if the drug reaches the market, while the pharmaceutical firm will hold the patent rights. The names of the 24 compounds in the pilot project will be disclosed next month, NIH said.
"NIH looks forward to working with our partners in industry and academia to tackle an urgent need that is beyond the scope of any one organization or sector," Collins said.
05.03.2012; Julie Steenhuysen, Anna Yukhananov
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.